Telix Pharmaceuticals

Telix Pharmaceuticals R&D per Employee

The R&D Spending per Employee of Telix Pharmaceuticals (TLX.AX) as of Oct 30, 2026 is 2.85 M USD. In the previous year, R&D Spending per Employee was 2.13 M USD — a change of 33.86% (higher).

R&D per Employee

2.85 MUSD

YoY

33.86%

Last updated:

R&D Spending per Employee of Telix Pharmaceuticals is 2025 2.85 M USD. R&D Spending per Employee of Telix Pharmaceuticals was 2024 2.13 M USD. It decreases by 33.86% higher compared to the previous year.

The Telix Pharmaceuticals R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
311,533.33 USD
Jan 1, 2019
352,700.00 USD
Jan 1, 2020
384,750.00 USD
Jan 1, 2021
568,916.67 USD
Jan 1, 2022
875,561.67 USD
Jan 1, 2023
1.42 M USD
Jan 1, 2024
2.13 M USD
Jan 1, 2025
2.85 M USD
The Telix Pharmaceuticals R&D per Employee history
YEARR&D per EmployeeYoY
2.85 MUSD+33.86%
2.13 MUSD+49.95%
1.42 MUSD+62.40%
875,561.67USD+53.90%
568,916.67USD+47.87%
384,750.00USD+9.09%
352,700.00USD+13.21%
311,533.33USD+527.86%
49,618.33USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telix Pharmaceuticals stock

R&D Spending per Employee of Telix Pharmaceuticals is 2.85 M USD in 2025.

R&D Spending per Employee of Telix Pharmaceuticals changed from 2.13 M USD to 2.85 M USD, representing a 33.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Telix Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals